Skip to main content

Loading market data...

IDXX

IDEXX Laboratories, Inc.

NASDAQ • United states

$554.07

-$3.86

(-0.69%)

Source: Yahoo Finance · Quote time Oct 21, 2026 14:46 GMT+0000

Management
Credibility
Score

IDEXX Laboratories, Inc. (IDXX)

Unavailable

Quotes may be delayed

$43.65B

Market Cap

88,963

Volume

38.3

P/E Ratio

Unavailable

Div Yield

IDEXX Laboratories, Inc. Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: ONE IDEXX DRIVE, WESTBROOK, ME
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

4 Aug 2026

IDEXX Laboratories, Inc. filed Form 10-Q

IDEXX Laboratories, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

4 Aug 2026

IDEXX Laboratories, Inc. reported Operating or financial results

IDEXX Laboratories, Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

15 May 2026

IDEXX Laboratories, Inc. reported A charter or bylaws change

IDEXX Laboratories, Inc. filed an 8-K covering a charter or bylaws change, shareholder voting results, supporting financial statements or exhibits.

5 May 2026

IDEXX Laboratories, Inc. filed Form 10-Q

IDEXX Laboratories, Inc. submitted Form 10-Q to the SEC for the period ending Mar 31, 2026.

5 May 2026

IDEXX Laboratories, Inc. reported Operating or financial results

IDEXX Laboratories, Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$196.93M

Total assets (USD)$3.44B

Total liabilities (USD)$1.83B

Shareholders' equity (USD)$1.61B

Long-term debt (USD)$299.87M

Debt due within a year (USD)$150.00M

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$1.22B	$425.57M	$338.41M	$4.27	10-Q · 4 Aug 2026
Q1 2026	$1.14B	$362.59M	$278.45M	$3.47	10-Q · 5 May 2026
Q4 2025	$1.09B	$315.61M	$248.19M	Unavailable	10-K · 20 Feb 2026
Q3 2025	$1.11B	$354.85M	$274.61M	$3.40	10-Q · 3 Nov 2025
Q2 2025	$1.11B	$373.05M	$293.99M	$3.63	10-Q · 4 Aug 2025
Q1 2025	$998.43M	$316.53M	$242.68M	$2.96	10-Q · 1 May 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $710.63

28.3% upside potential

📈

Strong Buy

Unavailable

👍

Buy

6

⏸️

Hold

4

📉

Sell

0

10 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 21 Oct 2026, 14:47 UTC Targets range 665.00–805.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

4

Sep 2026

Kingsley Lawrence D

Director

Option exercise

$114.17 per share

2,203 shares

4

Sep 2026

Kingsley Lawrence D

Director

Open-market sale

$532.08 per share

2,203 shares

20

Aug 2026

Emerson Andrew

EVP, CFO and Treasurer

Option exercise

$178.26 per share

265 shares

20

Aug 2026

Emerson Andrew

EVP, CFO and Treasurer

Tax withholding

Unavailable per share

86 shares

30

Jul 2026

HOOLEY JOSEPH L

Director

Grant or award

$558.80 per share

49 shares

1

Jun 2026

FENNELL GEORGE

Executive Vice President

Option exercise

Unavailable per share

639 shares

1

Jun 2026

FENNELL GEORGE

Executive Vice President

Tax withholding

$566.79 per share

284 shares

Top Shareholders

Vanguard Group Inc

9,945,328 shares

-0.168% change

12/31/2025

Blackrock, Inc.

8,170,178 shares

-2.335% change

6/30/2026

Vanguard Capital Management Llc

5,152,213 shares

-0.585% change

6/30/2026

Vanguard Portfolio Management Llc

3,896,521 shares

-0.367% change

6/30/2026

State Street Corp

3,748,660 shares

2.027% change

6/30/2026

Invesco Ltd.

3,611,416 shares

7.814% change

6/30/2026

Geode Capital Management, Llc

2,562,886 shares

-3.687% change

6/30/2026

Bamco Inc /Ny/

1,976,778 shares

21.025% change

6/30/2026

Morgan Stanley

1,356,103 shares

3.051% change

6/30/2026

Bank Of New York Mellon Corp

1,193,343 shares

-20.683% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 21 Oct 2026, 14:47 UTC· 17 hours ago

Research coverage and investment tools

IDEXX Laboratories, Inc. (IDXX) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances). Its last price was US$554.07 on 21 Oct 2026. That is 20% of the way from its 52-week low of US$500.61 to its 52-week high of US$769.98. Its market capitalisation was US$43.65 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$1.22B	$425.57M	$338.41M	$4.27	64.0%	35.0%	$322.52M	10-Q · 4 Aug 2026 (opens in a new tab)
Q1 2026	$1.14B	$362.59M	$278.45M	$3.47	63.4%	31.8%	$234.26M	10-Q · 5 May 2026 (opens in a new tab)
Q4 2025	$1.09B	$315.61M	$248.19M	Unavailable	60.3%	28.9%	$326.33M	10-K · 20 Feb 2026 (opens in a new tab)
Q3 2025	$1.11B	$354.85M	$274.61M	$3.40	61.8%	32.1%	$371.23M	10-Q · 3 Nov 2025 (opens in a new tab)
Q2 2025	$1.11B	$373.05M	$293.99M	$3.63	62.6%	33.6%	$151.64M	10-Q · 4 Aug 2025 (opens in a new tab)
Q1 2025	$998.43M	$316.53M	$242.68M	$2.96	62.4%	31.7%	$207.94M	10-Q · 1 May 2025 (opens in a new tab)

Quarter ended	Reported	EPS	Consensus	Surprise
Jun 2026	8/4/2026	$4.27	$3.95	+8.1%
Mar 2026	5/5/2026	$3.47	$3.42	+1.5%
Dec 2025	2/2/2026	$3.08	$2.93	+5.1%
Sep 2025	11/3/2025	$3.40	$3.14	+8.3%

Cash and equivalents: $196.93M
Total assets: $3.44B
Total liabilities: $1.83B
Shareholders' equity: $1.61B
Long-term debt: $299.87M
Debt due within a year: $150.00M

10-Q · 4 Aug 2026

IDEXX Laboratories, Inc. filed Form 10-Q (opens in a new tab)

IDEXX Laboratories, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
8-K · 4 Aug 2026

IDEXX Laboratories, Inc. reported Operating or financial results (opens in a new tab)

IDEXX Laboratories, Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.
8-K · 15 May 2026

IDEXX Laboratories, Inc. reported A charter or bylaws change (opens in a new tab)

IDEXX Laboratories, Inc. filed an 8-K covering a charter or bylaws change, shareholder voting results, supporting financial statements or exhibits.
10-Q · 5 May 2026

IDEXX Laboratories, Inc. filed Form 10-Q (opens in a new tab)

IDEXX Laboratories, Inc. submitted Form 10-Q to the SEC for the period ending Mar 31, 2026.
8-K · 5 May 2026

IDEXX Laboratories, Inc. reported Operating or financial results (opens in a new tab)

IDEXX Laboratories, Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

Insider	Date	Transaction	Shares	Average price	Filing
Kingsley Lawrence D Director	4 Sep 2026	Option exercise (M)	+2,203	$114.17	Form 4 (opens in a new tab)
Kingsley Lawrence D Director	4 Sep 2026	Open-market sale (S)	−2,203	$532.08	Form 4 (opens in a new tab)
Emerson Andrew EVP, CFO and Treasurer	20 Aug 2026	Option exercise (M)	+265	$178.26	Form 4 (opens in a new tab)
Emerson Andrew EVP, CFO and Treasurer	20 Aug 2026	Tax withholding (F)	−86	—	Form 4 (opens in a new tab)
HOOLEY JOSEPH L Director	30 Jul 2026	Grant or award (A)	+49	$558.80	Form 4 (opens in a new tab)
FENNELL GEORGE Executive Vice President	1 Jun 2026	Option exercise (M)	+639	—	Form 4 (opens in a new tab)
FENNELL GEORGE Executive Vice President	1 Jun 2026	Tax withholding (F)	−284	$566.79	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Vanguard Group Inc	12/31/2025	9,945,328	-0.168%
Blackrock, Inc.	6/30/2026	8,170,178	-2.335%
Vanguard Capital Management Llc	6/30/2026	5,152,213	-0.585%
Vanguard Portfolio Management Llc	6/30/2026	3,896,521	-0.367%
State Street Corp	6/30/2026	3,748,660	2.027%
Invesco Ltd.	6/30/2026	3,611,416	7.814%
Geode Capital Management, Llc	6/30/2026	2,562,886	-3.687%
Bamco Inc /Ny/	6/30/2026	1,976,778	21.025%
Morgan Stanley	6/30/2026	1,356,103	3.051%
Bank Of New York Mellon Corp	6/30/2026	1,193,343	-20.683%

Previous close: 557.93 USD
Day range: 547.60 – 560.17 USD
52-week range: 500.61 – 769.98 USD
Volume: 88,963
Market cap: $43.65B
Average volume: 505,450
P/E ratio: 38.3
EPS (FY 2025, diluted): 13.08 USD
Shares outstanding: 78.78M
Beta (5Y monthly): 1.55

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 21 Oct 2026, 14:46 UTC· 17 hours ago

Average volume and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:29 UTC· 1 hour ago

P/E is market cap ÷ trailing 12-month net income from SEC filings.

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for IDXX yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.